Plain-English translation of NCT07528209 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new immunotherapy drug called pucotenlimab, given together with standard chemotherapy () and sometimes radiation therapy, to treat locally advanced rectal cancer. The study compares patients who receive this medication combination to patients who receive chemotherapy and radiation alone. Researchers want to see if adding the medication helps shrink tumors more effectively and improve survival.
Standard treatment for advanced rectal cancer doesn't work well enough for all patients—some still develop distant cancer spread or have serious complications after surgery. This trial is exploring whether this medication can improve how well the body's immune system fights the cancer when combined with existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join the experimental group, you'll receive four cycles of chemotherapy plus the new medication over several weeks. Then doctors will scan your tumor to see how well it responded. Depending on your results, you may proceed directly to surgery, or you may receive short-course radiation followed by two more cycles of chemotherapy plus the medication before surgery. The control group receives the same chemotherapy and radiation plan without the new medication. After surgery, your doctor will decide on additional treatment. Throughout the trial, you'll have regular blood tests, imaging scans, and clinic visits to monitor your health and response to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China